Parker Hughes Cancer Center Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2000
NCT00004858
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

b43-genistein immunoconjugate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1